Based on the key indicators related to Standard Biotools' liquidity, profitability, solvency, and operating efficiency, Standard Biotools is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At present, Standard Biotools' Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 132 M, whereas Total Assets are forecasted to decline to about 228.8 M. Key indicators impacting Standard Biotools' financial strength include:
The financial analysis of Standard Biotools is a critical element in measuring its lifeblood. Investors should not minimize Standard Biotools' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Please note, the presentation of Standard Biotools' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Standard Biotools' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Standard Biotools' management manipulating its earnings.
Standard Biotools Stock Summary
Standard Biotools competes with Star Equity, Biodesix, ENDRA Life, Fonar, and MDxHealth. Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Standard Biotools operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 615 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Comparative valuation techniques use various fundamental indicators to help in determining Standard Biotools's current stock value. Our valuation model uses many indicators to compare Standard Biotools value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Standard Biotools competition to find correlations between indicators driving Standard Biotools's intrinsic value. More Info.
Standard Biotools is rated third overall in return on equity category among its peers. It is rated fifth overall in return on asset category among its peers . At present, Standard Biotools' Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Standard Biotools' earnings, one of the primary drivers of an investment's value.
Standard Biotools Systematic Risk
Standard Biotools' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Standard Biotools volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Standard Biotools correlated with the market. If Beta is less than 0 Standard Biotools generally moves in the opposite direction as compared to the market. If Standard Biotools Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Standard Biotools is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Standard Biotools is generally in the same direction as the market. If Beta > 1 Standard Biotools moves generally in the same direction as, but more than the movement of the benchmark.
Standard Biotools Thematic Clasifications
Standard Biotools is part of Measuring and Control Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Measuring and Control Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Today, most investors in Standard Biotools Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Standard Biotools' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Standard Biotools growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0418
At present, Standard Biotools' Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Standard Biotools February 1, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Standard Biotools help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Standard Biotools. We use our internally-developed statistical techniques to arrive at the intrinsic value of Standard Biotools based on widely used predictive technical indicators. In general, we focus on analyzing Standard Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Standard Biotools's daily price indicators and compare them against related drivers.
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.